GENCURIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,945 KRW | -1.17% |
|
-4.38% | -52.65% |
| Sales 2022 | 2.56B 1.86M | Sales 2023 | 2.6B 1.89M | Capitalization | 84.35B 61.33M |
|---|---|---|---|---|---|
| Net income 2022 | -24.6B -17.88M | Net income 2023 | -19.26B -14M | EV / Sales 2022 | 26.8 x |
| Net Debt 2022 | 22.55B 16.39M | Net Debt 2023 | 5.63B 4.1M | EV / Sales 2023 | 34.6 x |
| P/E ratio 2022 |
-1.86
x | P/E ratio 2023 |
-3.82
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.17% | ||
| 1 week | -4.38% | ||
| Current month | -4.38% | ||
| 1 month | -7.10% | ||
| 3 months | -28.69% | ||
| 6 months | -49.05% | ||
| Current year | -52.65% |
1 week
2 910.00
3 065.00
1 month
2 910.003 450.00
Current year
2 820.006 340.00
1 year
2 700.008 910.00
3 years
2 700.0024 700.00
5 years
2 700.0027 500.00
10 years
2 700.0032 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Rae Cho
CEO | Chief Executive Officer | 51 | - |
Jong-Heun Lee
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Young-Ho Moon
CTO | Chief Tech/Sci/R&D Officer | 62 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myung-Hwan Kim
BRD | Director/Board Member | 54 | - |
Sang-Rae Cho
CEO | Chief Executive Officer | 51 | - |
Young-Ho Moon
CTO | Chief Tech/Sci/R&D Officer | 62 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 2,945 | -1.17% | 67,583 |
| 24-06-05 | 2,980 | -0.83% | 76,035 |
| 24-06-04 | 3,005 | -2.44% | 45,213 |
| 24-06-03 | 3,080 | 0.00% | 52,773 |
End-of-day quote Korea S.E., June 06, 2024
More quotes
Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.
Calendar
2024-11-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -52.65% | 30.87M | |
| -7.46% | 11.98B | |
| -5.68% | 8B | |
| +7.79% | 5.85B | |
| +28.87% | 5.54B | |
| -15.84% | 3.84B | |
| +10.70% | 2.66B | |
| -60.92% | 2.62B | |
| -8.17% | 2.33B | |
| -8.85% | 1.78B |
- Stock Market
- Equities
- A229000 Stock
